Ad Header



The Pulse of the Pharmaceutical Industry

Bayer to work with Foundation Medicine

Written by: | | Dated: Wednesday, May 29th, 2019


Bayer to work with Foundation Medicine on selecting cancer patients


RANKFURT (Reuters) – Bayer struck a collaboration deal with Roche’s Foundation Medicine Inc. to develop test kits for genetic sequencing of tumor cells to identify cancer patients that benefit from Bayer’s Vitrakvi drug.

Vitrakvi, which Bayer acquired from Eli Lilly’s Loxo Oncology, has been shown to shrink tumors in about 1 percent of patients across a range 24 different cancer types. Identifying those patients requires advanced genetic diagnostic tools.


Reporting by Ludwig Burger; Editing by Thomas Seythal


Reuters source:

Ad Right Top


Extensive pharmaceutical business and marketing intelligence. For back issues, please contact

August 2019 Focus: AI, AR/VR, Top 200 Medicines, Lions Health Takeaways, and more!


Ad Right Bottom